A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Public ClinicalTrials.gov record NCT05557045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Study identification
- NCT ID
- NCT05557045
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 98 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2022
- Primary completion
- Mar 31, 2028
- Completion
- Mar 31, 2028
- Last update posted
- Sep 9, 2026
2022 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| SCRI HealthOne | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists - Lake Nona | Orlando | Florida | 32827 | — |
| Florida Cancer Specialists - Sarasota | Sarasota | Florida | 34232 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Oklahoma University | Oklahoma City | Oklahoma | 73104 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| Tennessee Oncology - Nashville | Nashville | Tennessee | 37203 | — |
| Texas Oncology- Central South | Austin | Texas | 78731 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology- Gulf Coast | The Woodlands | Texas | 77380 | — |
| Virginica Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05557045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05557045 live on ClinicalTrials.gov.